iBody is a biotechnology company with a proprietary, high-performance monoclonal antibody discovery platform, offering antibody discovery services as part of its business model.
Our technology integrates single-cell technology with cell-free antibody expression, enabling highly comprehensive and rapid antibody screening. This allows us to efficiently identify valuable antibodies from humans and animals without losing essential ones. Therefore, we are able to discover highly difficult antibodies that are difficult to obtain using conventional methods.
Furthermore, because the entire process is performed in vitro, antibody screening can be performed technically in as little as two days — one of the fastest timelines in the world.
Using this technology, we have successfully identified highly specific monoclonal antibodies against small molecule antigens, post-translational modifications such as phosphorylation, and even ultra-specific antibodies targeting therapeutic antibodies.
The strength of our technology has been recognized by major global pharmaceutical and diagnostic companies in Japan, with whom we have already initiated collaborative projects.
In addition, since 2023, we established the strategic business and capital alliance with TAUNS Laboratories that is one of the leading companies in the in vitro diagnostics field (IVD) in Japan, and we are expected to expand our business further through this partnership.
Our proprietary technology is patented not only in Japan but also in the United States and Europe, maintaining a competitive edge over other players in the market.
Finally, as the markets for antibody therapeutics and diagnostic reagents that utilize antibodies are expected to grow significantly, the demand for antibody discovery will continue to rise. iBody will contribute to driving innovation in therapeutic and diagnostic development through our proprietary antibody discovery technology.